bicalutamide ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
non-steroid antiandrogens 367 90357-06-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ICI 176334
  • ICI-176334
  • bicalutamide
  • casodex
Bicalutamide is a non-steroidal androgen receptor inhibitor. It competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen.
  • Molecular weight: 430.37
  • Formula: C18H14F4N2O4S
  • CLOGP: 2.71
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 107.26
  • ALOGS: -4.67
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.94 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Oct. 4, 1995 FDA ASTRAZENECA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prostatic specific antigen increased 1075.82 12.95 404 25135 14276 34917116
Metastases to bone 385.89 12.95 184 25355 11786 34919606
Osteonecrosis of jaw 351.18 12.95 197 25342 17692 34913700
Prostate cancer metastatic 340.25 12.95 136 25403 5667 34925725
Prostate cancer 329.62 12.95 255 25284 39394 34891998
Hot flush 265.41 12.95 165 25374 17901 34913491
Interstitial lung disease 259.03 12.95 277 25262 65005 34866387
Malignant neoplasm progression 250.98 12.95 315 25224 87731 34843661
Hormone-refractory prostate cancer 128.43 12.95 39 25500 701 34930691
Osteonecrosis 106.96 12.95 88 25451 14802 34916590
Prostate cancer recurrent 93.08 12.95 33 25506 980 34930412
Blood testosterone increased 92.93 12.95 35 25504 1238 34930154
Bone lesion 78.86 12.95 40 25499 2923 34928469
Haematuria 76.75 12.95 134 25405 49932 34881460
Prostatic specific antigen abnormal 76.02 12.95 26 25513 692 34930700
Torsade de pointes 74.68 12.95 53 25486 7156 34924236
Toxicity to various agents 69.10 12.95 30 25509 200332 34731060
Tooth extraction 63.92 12.95 41 25498 4687 34926705
Bone disorder 62.79 12.95 45 25494 6170 34925222
Metastases to lymph nodes 61.45 12.95 40 25499 4688 34926704
Drug abuse 59.94 12.95 3 25536 99093 34832299
Gynaecomastia 58.56 12.95 53 25486 10127 34921265
Hepatic function abnormal 54.52 12.95 108 25431 44255 34887137
Bone pain 52.48 12.95 70 25469 20616 34910776
Breast cancer male 51.80 12.95 17 25522 397 34930995
Metastasis 51.28 12.95 34 25505 4110 34927282
Blood testosterone abnormal 50.86 12.95 17 25522 421 34930971
Hypocalcaemia 49.48 12.95 74 25465 24215 34907177
Hydronephrosis 48.32 12.95 48 25491 10298 34921094
Metastases to spine 46.73 12.95 27 25512 2557 34928835
Disease progression 46.66 12.95 179 25360 107898 34823494
Completed suicide 46.25 12.95 8 25531 98160 34833232
Metastases to lung 44.94 12.95 44 25495 9276 34922116
Anti-androgen withdrawal syndrome 44.76 12.95 8 25531 7 34931385
Exposed bone in jaw 43.93 12.95 22 25517 1564 34929828
Urinary retention 39.45 12.95 84 25455 36204 34895188
Pain in jaw 37.57 12.95 47 25492 12993 34918399
Anaemia 35.91 12.95 292 25247 233043 34698349
Breast tenderness 34.80 12.95 15 25524 756 34930636
Injection site induration 34.27 12.95 23 25516 2837 34928555
Cardiac failure 33.68 12.95 144 25395 91104 34840288
Pituitary haemorrhage 32.41 12.95 10 25529 190 34931202
Metastases to liver 31.28 12.95 44 25495 13619 34917773
Osteomyelitis 31.21 12.95 48 25491 16088 34915304
Electrocardiogram QT prolonged 30.65 12.95 82 25457 40870 34890522
Polyneuropathy in malignant disease 30.41 12.95 10 25529 235 34931157
Central nervous system mass 29.22 12.95 9 25530 170 34931222
Wall motion score index abnormal 29.07 12.95 9 25530 173 34931219
Breast swelling 28.76 12.95 10 25529 280 34931112
Asthenia 28.09 12.95 288 25251 244963 34686429
Spinal cord compression 27.51 12.95 23 25516 3952 34927440
Urinary tract obstruction 27.26 12.95 22 25517 3598 34927794
Retroperitoneal lymphadenopathy 27.10 12.95 13 25526 841 34930551
Sequestrectomy 26.81 12.95 9 25530 226 34931166
Airway remodelling 26.66 12.95 9 25530 230 34931162
Atopy 26.19 12.95 9 25530 243 34931149
Muscular weakness 26.09 12.95 114 25425 72783 34858609
Hyperthyroidism 25.64 12.95 35 25504 10531 34920861
Neuroendocrine carcinoma of prostate 25.31 12.95 5 25534 11 34931381
Bone sequestrum 25.21 12.95 11 25528 571 34930821
Intercepted product preparation error 24.97 12.95 22 25517 4056 34927336
Osteosclerosis 24.38 12.95 14 25525 1310 34930082
Cystitis radiation 24.29 12.95 7 25532 104 34931288
Injection site abscess 24.17 12.95 12 25527 837 34930555
Cardiac septal defect 24.12 12.95 9 25530 310 34931082
Off label use 24.02 12.95 194 25345 419330 34512062
Blood alkaline phosphatase increased 23.91 12.95 63 25476 31112 34900280
Gingivitis 23.33 12.95 20 25519 3555 34927837
COVID-19 23.12 12.95 14 25525 77536 34853856
Radiation injury 22.94 12.95 10 25529 518 34930874
Phyllodes tumour 22.65 12.95 4 25535 3 34931389
Cerebral infarction 22.62 12.95 57 25482 27398 34903994
Abscess jaw 22.41 12.95 11 25528 749 34930643
Osteitis 21.90 12.95 14 25525 1590 34929802
Testicular atrophy 21.84 12.95 10 25529 582 34930810
Metastases to eye 21.70 12.95 6 25533 76 34931316
Neuroendocrine carcinoma 21.57 12.95 9 25530 418 34930974
Metastases to soft tissue 21.39 12.95 9 25530 427 34930965
Cholangitis sclerosing 20.90 12.95 13 25526 1408 34929984
Metastases to breast 20.85 12.95 4 25535 7 34931385
Troponin increased 20.80 12.95 33 25506 11356 34920036
Decreased appetite 20.76 12.95 199 25340 166193 34765199
Loss of libido 20.26 12.95 16 25523 2536 34928856
Bone debridement 20.03 12.95 7 25532 199 34931193
Toothache 19.98 12.95 24 25515 6364 34925028
Product monitoring error 19.85 12.95 20 25519 4361 34927031
Infusion related reaction 19.80 12.95 7 25532 53050 34878342
Cancer pain 19.62 12.95 16 25523 2656 34928736
Eosinophilic myocarditis 19.35 12.95 9 25530 543 34930849
Hyperadrenalism 19.07 12.95 5 25534 51 34931341
Radiation proctitis 19.02 12.95 6 25533 123 34931269
Dysuria 18.94 12.95 53 25486 27099 34904293
Radical prostatectomy 18.90 12.95 5 25534 53 34931339
Fatigue 18.76 12.95 377 25162 370276 34561116
Anaesthesia 18.73 12.95 5 25534 55 34931337
Disseminated intravascular coagulation 18.71 12.95 46 25493 21770 34909622
Product dose omission issue 18.68 12.95 37 25502 119674 34811718
Bone trimming 18.67 12.95 3 25536 0 34931392
Androgens increased 18.67 12.95 3 25536 0 34931392
Purulent discharge 18.65 12.95 16 25523 2847 34928545
Conjunctival ulcer 18.49 12.95 5 25534 58 34931334
Bone swelling 18.47 12.95 7 25532 252 34931140
Pneumonia 18.37 12.95 173 25366 362454 34568938
Breast pain 18.36 12.95 12 25527 1416 34929976
Adrenal insufficiency 18.21 12.95 35 25504 14012 34917380
Jaw disorder 18.06 12.95 14 25525 2161 34929231
Abdominal wall haematoma 17.86 12.95 13 25526 1824 34929568
Haemorrhage urinary tract 17.63 12.95 13 25526 1861 34929531
Gingival swelling 17.21 12.95 11 25528 1249 34930143
Back pain 16.87 12.95 149 25390 121640 34809752
Cough 16.78 12.95 55 25484 150085 34781307
Bone fistula 16.72 12.95 4 25535 27 34931365
Sepsis 16.63 12.95 64 25475 166497 34764895
Ureteric rupture 16.59 12.95 3 25536 3 34931389
Drug hypersensitivity 16.23 12.95 21 25518 80508 34850884
Intentional product use issue 16.21 12.95 12 25527 59804 34871588
Rheumatoid arthritis 16.17 12.95 4 25535 38234 34893158
Overdose 16.13 12.95 26 25513 91033 34840359
Breakthrough pain 15.94 12.95 8 25531 571 34930821
Respiratory symptom 15.87 12.95 12 25527 1785 34929607
Quality of life decreased 15.86 12.95 17 25522 3984 34927408
Oral surgery 15.81 12.95 8 25531 581 34930811
Hydroureter 15.70 12.95 7 25532 383 34931009
Debridement 15.18 12.95 9 25530 894 34930498
Neuroendocrine carcinoma metastatic 15.15 12.95 5 25534 119 34931273
Prescribed underdose 15.11 12.95 25 25514 8908 34922484
Injection site ulcer 14.86 12.95 6 25533 256 34931136
Microangiopathy 14.72 12.95 9 25530 945 34930447
Pathological fracture 14.56 12.95 17 25522 4374 34927018
Pelvic pain 14.43 12.95 13 25526 2467 34928925
Eye colour change 14.42 12.95 6 25533 277 34931115
Oral infection 14.30 12.95 12 25527 2071 34929321
Dental care 14.21 12.95 6 25533 287 34931105
Syringe issue 14.10 12.95 19 25520 5645 34925747
Urogenital haemorrhage 14.05 12.95 8 25531 737 34930655
Orchidectomy 14.03 12.95 4 25535 57 34931335
Therapeutic product effect incomplete 13.88 12.95 10 25529 50531 34880861
Prostatic specific antigen decreased 13.87 12.95 5 25534 156 34931236
Paraneoplastic dermatomyositis 13.84 12.95 4 25535 60 34931332
Death 13.72 12.95 384 25155 397665 34533727
Metastases to spinal cord 13.66 12.95 3 25536 13 34931379
Coccydynia 13.53 12.95 7 25532 533 34930859
Vipoma 13.47 12.95 3 25536 14 34931378
Product name confusion 13.38 12.95 4 25535 68 34931324
Device leakage 13.34 12.95 20 25519 6555 34924837
Allodynia 13.24 12.95 8 25531 823 34930569
Suicide attempt 13.22 12.95 6 25533 39110 34892282
Gingival abscess 13.19 12.95 5 25534 180 34931212
Poor peripheral circulation 13.17 12.95 10 25529 1497 34929895
Rash 13.16 12.95 102 25437 222650 34708742

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prostatic specific antigen increased 1190.31 13.67 315 20346 10071 79713656
Prostate cancer 460.57 13.67 207 20454 33061 79690666
Osteonecrosis of jaw 304.20 13.67 170 20491 43056 79680671
Metastases to bone 291 13.67 137 20524 24290 79699437
Prostate cancer metastatic 290.65 13.67 85 20576 3922 79719805
Interstitial lung disease 279.22 13.67 232 20429 112368 79611359
Malignant neoplasm progression 220.86 13.67 221 20440 135769 79587958
Hot flush 172.24 13.67 130 20531 54747 79668980
Hormone-refractory prostate cancer 125.00 13.67 28 20633 432 79723295
Blood testosterone increased 116.05 13.67 31 20630 1021 79722706
Haematuria 111.83 13.67 112 20549 68724 79655003
Prostate cancer recurrent 104.11 13.67 27 20634 791 79722936
Gynaecomastia 82.05 13.67 40 20621 7641 79716086
Torsade de pointes 79.52 13.67 54 20607 19258 79704469
Disease progression 76.68 13.67 156 20505 184206 79539521
Hepatic function abnormal 74.06 13.67 93 20568 73014 79650713
Prostatic specific antigen abnormal 67.42 13.67 17 20644 444 79723283
Urinary retention 67.09 13.67 78 20583 56552 79667175
Osteonecrosis 60.69 13.67 56 20605 31039 79692688
Anaemia 58.45 13.67 249 20412 444766 79278961
Death 56.14 13.67 292 20369 566222 79157505
Metastasis 53.69 13.67 29 20632 6851 79716876
Anti-androgen withdrawal syndrome 53.04 13.67 8 20653 7 79723720
Hypocalcaemia 51.33 13.67 64 20597 49860 79673867
Cardiac failure 50.66 13.67 119 20542 154723 79569004
Metastases to lung 50.34 13.67 40 20621 18123 79705604
Metastases to lymph nodes 49.91 13.67 32 20629 10365 79713362
Hydronephrosis 49.58 13.67 39 20622 17415 79706312
Bone lesion 43.56 13.67 24 20637 5895 79717832
Intercepted product preparation error 42.46 13.67 20 20641 3540 79720187
Rheumatoid arthritis 42.40 13.67 3 20658 208467 79515260
Completed suicide 41.30 13.67 7 20654 245760 79477967
Toxicity to various agents 40.61 13.67 30 20631 421510 79302217
Infusion related reaction 39.94 13.67 6 20655 230231 79493496
Polyneuropathy in malignant disease 39.06 13.67 10 20651 278 79723449
Asthenia 38.96 13.67 246 20415 511443 79212284
Wall motion score index abnormal 38.31 13.67 9 20652 173 79723554
Pituitary haemorrhage 38.29 13.67 10 20651 301 79723426
Central nervous system mass 38.26 13.67 9 20652 174 79723553
Breast cancer male 37.62 13.67 10 20651 323 79723404
Alopecia 35.90 13.67 8 20653 231347 79492380
Erectile dysfunction 35.81 13.67 30 20631 14634 79709093
Hyperthyroidism 35.79 13.67 36 20625 22173 79701554
Blood testosterone abnormal 35.55 13.67 9 20652 239 79723488
Electrocardiogram QT prolonged 34.62 13.67 74 20587 90312 79633415
Troponin increased 34.36 13.67 33 20628 19222 79704505
Sinusitis 34.13 13.67 5 20656 195496 79528231
Airway remodelling 34.03 13.67 9 20652 285 79723442
Hypersensitivity 33.52 13.67 13 20648 262226 79461501
Exposed bone in jaw 32.76 13.67 17 20644 3703 79720024
Cardiac septal defect 32.68 13.67 9 20652 333 79723394
Loss of libido 31.77 13.67 15 20646 2670 79721057
Joint swelling 31.23 13.67 18 20643 288628 79435099
Atopy 30.44 13.67 9 20652 431 79723296
Bone pain 30.39 13.67 53 20608 55689 79668038
Metastases to spine 30.36 13.67 17 20644 4307 79719420
Headache 29.57 13.67 80 20581 653692 79070035
Drug hypersensitivity 29.12 13.67 21 20640 298895 79424832
Therapeutic product effect decreased 29.04 13.67 4 20657 163859 79559868
Nasopharyngitis 28.67 13.67 15 20646 253866 79469861
Metastases to liver 28.62 13.67 36 20625 28278 79695449
Adrenal insufficiency 28.45 13.67 36 20625 28451 79695276
Acute myocardial infarction 28.28 13.67 62 20599 76974 79646753
Drug intolerance 27.82 13.67 17 20644 264102 79459625
Neuroendocrine carcinoma 27.57 13.67 9 20652 599 79723128
Testicular atrophy 27.47 13.67 8 20653 363 79723364
Syringe issue 26.85 13.67 18 20643 6280 79717447
Urinary tract obstruction 26.23 13.67 16 20645 4749 79718978
Cholangitis sclerosing 25.98 13.67 13 20648 2624 79721103
Product monitoring error 25.51 13.67 20 20641 8886 79714841
Blood alkaline phosphatase increased 25.39 13.67 53 20608 63611 79660116
Drug interaction 25.25 13.67 189 20472 414994 79308733
Disseminated intravascular coagulation 24.85 13.67 38 20623 35804 79687923
Radiation injury 24.69 13.67 9 20652 834 79722893
Dysuria 24.65 13.67 46 20615 50905 79672822
Radiation proctitis 24.32 13.67 6 20655 143 79723584
Decreased appetite 23.79 13.67 161 20500 342257 79381470
Neuroendocrine carcinoma of prostate 23.75 13.67 4 20657 11 79723716
Metastases to soft tissue 23.57 13.67 8 20653 601 79723126
Cystitis radiation 22.59 13.67 6 20655 193 79723534
Prostatic specific antigen decreased 22.58 13.67 5 20656 73 79723654
Conjunctival ulcer 22.09 13.67 5 20656 81 79723646
Bone disorder 22.08 13.67 26 20635 19087 79704640
Tooth extraction 21.83 13.67 20 20641 10975 79712752
Androgens increased 21.78 13.67 3 20658 0 79723727
Platelet count decreased 21.77 13.67 104 20557 194560 79529167
Bone debridement 21.71 13.67 7 20654 448 79723279
Acute coronary syndrome 21.57 13.67 27 20634 21106 79702621
Eosinophilic myocarditis 21.44 13.67 9 20652 1213 79722514
Product use issue 21.41 13.67 14 20647 209808 79513919
Lower respiratory tract infection 21.00 13.67 4 20657 129216 79594511
Haemorrhage urinary tract 20.97 13.67 11 20650 2450 79721277
Metastases to eye 20.85 13.67 6 20655 261 79723466
Phyllodes tumour 20.60 13.67 4 20657 29 79723698
Orchidectomy 20.48 13.67 4 20657 30 79723697
Breast swelling 20.39 13.67 9 20652 1371 79722356
Diabetes mellitus 20.13 13.67 55 20606 78335 79645392
Cancer pain 20.02 13.67 14 20647 5231 79718496
Urogenital haemorrhage 19.88 13.67 8 20653 969 79722758
Blood lactate dehydrogenase increased 19.75 13.67 36 20625 39134 79684593
Off label use 19.24 13.67 147 20514 907068 78816659
Rash 19.13 13.67 81 20580 578277 79145450
Hydroureter 19.02 13.67 7 20654 666 79723061
Breast tenderness 18.93 13.67 10 20651 2258 79721469
Hyperadrenalism 18.56 13.67 4 20657 51 79723676
Product name confusion 18.39 13.67 5 20656 176 79723551
COVID-19 18.26 13.67 9 20652 157665 79566062
Contraindicated product administered 18.23 13.67 9 20652 157529 79566198
Muscular weakness 18.06 13.67 86 20575 160643 79563084
Syncope 18.02 13.67 93 20568 179356 79544371
Abdominal pain upper 17.83 13.67 19 20642 223800 79499927
Microangiopathy 17.81 13.67 9 20652 1856 79721871
Spinal cord compression 17.57 13.67 14 20647 6363 79717364
Breakthrough pain 17.34 13.67 8 20653 1351 79722376
Bone cancer 17.16 13.67 9 20652 2003 79721724
Paraneoplastic dermatomyositis 17.07 13.67 4 20657 76 79723651
Cerebral infarction 17.03 13.67 37 20624 45639 79678088
Metastases to central nervous system 16.84 13.67 21 20640 16354 79707373
Vipoma 16.58 13.67 3 20658 14 79723713
Respiratory symptom 16.47 13.67 12 20649 4779 79718948
Radical prostatectomy 16.41 13.67 3 20658 15 79723712
Device leakage 16.40 13.67 17 20644 10839 79712888
Pemphigus 16.36 13.67 3 20658 99579 79624148
Osteomyelitis 16.31 13.67 30 20631 32835 79690892
Abdominal wall haematoma 16.29 13.67 12 20649 4861 79718866
Metastases to breast 16.08 13.67 5 20656 284 79723443
Subdural haematoma 15.98 13.67 29 20632 31405 79692322
Pollakiuria 15.98 13.67 32 20629 37285 79686442
Injection site induration 15.97 13.67 16 20645 9803 79713924
Allodynia 15.87 13.67 8 20653 1640 79722087
Retroperitoneal lymphadenopathy 15.69 13.67 7 20654 1093 79722634
Product dose omission issue 15.62 13.67 25 20636 247512 79476215
Penile oedema 15.60 13.67 5 20656 314 79723413
Hypogonadism 15.38 13.67 8 20653 1752 79721975
Libido decreased 15.35 13.67 12 20649 5309 79718418
Therapeutic product effect incomplete 15.07 13.67 9 20652 141636 79582091
Cough 15.00 13.67 47 20614 366742 79356985
Bone sequestrum 14.95 13.67 7 20654 1222 79722505
Bone trimming 14.88 13.67 3 20658 27 79723700
Neuroendocrine carcinoma metastatic 14.74 13.67 5 20656 375 79723352
Myoclonus 14.68 13.67 26 20635 27634 79696093
Poor peripheral circulation 14.45 13.67 10 20651 3673 79720054
Ventricular fibrillation 14.42 13.67 28 20633 31898 79691829
Eye colour change 14.35 13.67 5 20656 406 79723321
Bronchitis 14.33 13.67 8 20653 130636 79593091
Tooth loss 14.30 13.67 13 20648 7062 79716665
Anxiety 13.96 13.67 27 20634 248485 79475242
Osteitis 13.84 13.67 10 20651 3933 79719794
Formication 13.78 13.67 11 20650 5012 79718715

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L02AE51 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONES AND RELATED AGENTS
Gonadotropin releasing hormone analogues
ATC L02BB03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONE ANTAGONISTS AND RELATED AGENTS
Anti-androgens
FDA MoA N0000000243 Androgen Receptor Antagonists
FDA EPC N0000175560 Androgen Receptor Inhibitor
CHEBI has role CHEBI:35497 antiandrogen
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:78298 environmental contaminants
MeSH PA D000726 Androgen Antagonists
MeSH PA D000970 Antineoplastic Agents
MeSH PA D006727 Hormone Antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Metastatic Prostate Carcinoma indication
Advanced Prostatic Carcinoma off-label use
Interstitial pneumonia contraindication 64667001
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.19 acidic
pKa2 11.84 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Androgen receptor Nuclear hormone receptor ANTAGONIST Ki 7.72 CHEMBL CHEMBL
Cytochrome P450 2C19 Enzyme IC50 6 CHEMBL
Androgen receptor Transcription factor Ki 7.85 CHEMBL
Androgen receptor Transcription factor IC50 6.17 CHEMBL
Progesterone receptor Transcription factor IC50 5.25 CHEMBL
Progesterone receptor Transcription factor Ki 5.14 CHEMBL

External reference:

IDSource
4020950 VUID
N0000148428 NUI
D00961 KEGG_DRUG
151495 RXNORM
C0285590 UMLSCUI
CHEBI:3090 CHEBI
CHEMBL409 ChEMBL_ID
CHEMBL63560 ChEMBL_ID
DB01128 DRUGBANK_ID
C053541 MESH_SUPPLEMENTAL_RECORD_UI
2375 PUBCHEM_CID
2863 IUPHAR_LIGAND_ID
7021 INN_ID
A0Z3NAU9DP UNII
165839 MMSL
4282 MMSL
4824 MMSL
d03850 MMSL
108766001 SNOMEDCT_US
386908000 SNOMEDCT_US
4020950 VANDF
005064 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 0904-6019 TABLET 50 mg ORAL ANDA 26 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 0904-6019 TABLET 50 mg ORAL ANDA 26 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 16714-816 TABLET, FILM COATED 50 mg ORAL ANDA 28 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 16729-023 TABLET 50 mg ORAL ANDA 26 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 16729-023 TABLET 50 mg ORAL ANDA 26 sections
bicalutamide Human Prescription Drug Label 1 47335-485 TABLET, FILM COATED 50 mg ORAL ANDA 26 sections
CASODEX HUMAN PRESCRIPTION DRUG LABEL 1 54868-4503 TABLET 50 mg ORAL NDA 25 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 54868-6133 TABLET, FILM COATED 50 mg ORAL ANDA 28 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 60429-177 TABLET, FILM COATED 50 mg ORAL ANDA 26 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 60429-177 TABLET, FILM COATED 50 mg ORAL ANDA 26 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 60429-177 TABLET, FILM COATED 50 mg ORAL ANDA 26 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 60505-2642 TABLET 50 mg ORAL ANDA 26 sections
bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 62175-132 TABLET, FILM COATED 50 mg ORAL ANDA 26 sections
CASODEX HUMAN PRESCRIPTION DRUG LABEL 1 62559-680 TABLET 50 mg ORAL NDA 27 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 62559-890 TABLET 50 mg ORAL NDA 27 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8308 TABLET 50 mg ORAL ANDA 25 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8308 TABLET 50 mg ORAL ANDA 25 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 63672-0005 TABLET, FILM COATED 50 mg ORAL ANDA 28 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 65841-613 TABLET, FILM COATED 50 mg ORAL ANDA 1 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 65841-613 TABLET, FILM COATED 50 mg ORAL ANDA 1 sections
bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 67253-191 TABLET, FILM COATED 50 mg ORAL ANDA 28 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 68382-224 TABLET, FILM COATED 50 mg ORAL ANDA 28 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 68382-224 TABLET, FILM COATED 50 mg ORAL ANDA 28 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 70518-2993 TABLET 50 mg ORAL ANDA 25 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 71205-577 TABLET 50 mg ORAL ANDA 26 sections
Bicalutamide HUMAN PRESCRIPTION DRUG LABEL 1 71205-577 TABLET 50 mg ORAL ANDA 26 sections